Home / Market News / $ELV
fiscal.ai Corporate Catalyst Impact 55/100 ● positive

Truist Raises Price Target on Elevance Health to $500

Oct 22, 2026, 1:33 PM UTC · Primary ticker $ELV

Truist Securities has increased its price target for Elevance Health (ELV) from $475 to $500, while reiterating a Buy rating. This analyst upgrade reflects an updated positive outlook on the health insurance provider, suggesting potential upside for the stock based on the firm's valuation models.

Truist Securities, a prominent financial institution, has raised its price target on Elevance Health (ELV) to $500 from $475, maintaining a 'Buy' rating. This adjustment signals increased confidence from the analyst firm regarding ELV's future performance and valuation. For traders, this could be a short-term positive catalyst, potentially leading to increased buying interest as investors react to the updated target. Long-term implications depend on whether the company's fundamentals align with this optimistic outlook, but it generally reinforces a positive sentiment around the stock. The key opportunity for traders is to capitalize on any immediate upward momentum following this analyst action.

$ELV positive Price target increase
Source: fiscal.ai
Join the waitlist for full signal validation →

Not financial advice. AI-generated analysis for informational purposes only.